IL-17A and IL-25: Therapeutic targets for allergic and exacerbated asthmatic disease

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 833-836

  Petersen, Bryan C ^a   Lukacs, Nicholas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

allergy; asthma; chemokines; IL 17A; IL 25

Indexed keywords

ALLERGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CXCL1 CHEMOKINE; EOTAXIN; GLUCOCORTICOID; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 25; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STEROID;

ADAPTIVE IMMUNITY; AIRWAY; ALLERGIC ASTHMA; APOPTOSIS; ASTHMA; ATOPIC DERMATITIS; BASOPHIL; BRONCHUS HYPERREACTIVITY; CHURG STRAUSS SYNDROME; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TARGETING; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; LUNG; LUNG ALVEOLUS CELL; LUNG ALVEOLUS MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TH2 CELL; TREATMENT FAILURE; VIRAL RESPIRATORY TRACT INFECTION;

ALLERGENS; ASTHMA; DISEASE PROGRESSION; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-17; LUNG; MOLECULAR TARGETED THERAPY; MUCUS; RECEPTORS, CHEMOKINE; RESPIRATORY SYSTEM;

EID: 84861054351     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.39     Document Type: Review

References (26)

1. Mukherjee S, Lindell DM, Berlin AA et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am. J. Pathol. 179(1), 248-258 (2011
2. Lukacs NW. Role of chemokines in the pathogenesis of asthma. Nat. Rev. Immunol. 1(2), 108-116 (2001
3. Pelletier M, Maggi L, Micheletti A et al. Evidence for a cross-Talk between human neutrophils and Th17 cells. Blood 115(2), 335-343 (2010
4. Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 180(8), 720-730 (2009
5. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. Nat. Immunol. 10(12), 1245-1251 (2009
6. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 9(8), 556-567 (2009
7. Song X, Zhu S, Shi P et al. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat. Immunol. 12(12), 1151-1158 (2011
8. Rickel EA, Siegel LA, Yoon BR et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 181(6), 4299-4310 (2008
9. Fort MM, Cheung J, Yen D et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-Associated pathologies in vivo. Immunity 15(6), 985-995 (2001
10. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-Type allergic inflammation via epithelial-derived IL-25. J. Immunol. 185(8), 4681-4690 (2010
11. Ballantyne SJ, Barlow JL, Jolin HE et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120(6), 1324-1331 (2007
12. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2(5), 403-411 (2009
13. Fujie H, Niu K, Ohba M et al. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation doi:101007/s1075301194190 (2012) (Epub ahead of print
14. Mjosberg JM, Trifari S, Crellin NK et al. Human IL-25-And IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. 12(11), 1055-1062 (2011
15. Lee JW, Wang P, Kattah MG et al. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J. Immunol. 181(9), 6536-6545 (2008
16. Zhao Y, Yang J, Gao YD, Guo W. Th17 immunity in patients with allergic asthma. Int. Arch. Allergy Immunol. 151(4), 297-307 (2010
17. McKinley L, Alcorn JF, Peterson A et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 181(6), 4089-4097 (2008
18. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: A possible link between inflammation and skin barrier dysfunction? J. Invest. Dermatol. 131(1), 150-157 (2011
19. Terrier B, Bieche I, Maisonobe T et al. Interleukin-25: A cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 116(22), 4523-4531 (2010
20. Corrigan CJ, Wang W, Meng Q et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J. Allergy Clin. Immunol. 128(1), 116-124 (2011
21. Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Top. Med. Chem. 6(13), 1345-1352 (2006
22. Hwang SY, Kim JY, Kim KW et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kB-And PI3-kinase/Akt- dependent pathways. Arthritis Res. Ther. 6(2), R120-R128 (2004
23. Laan M, Cui ZH, Hoshino H et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 162(4), 2347-2352 (1999
24. Sahin H, Berres ML, Wasmuth HE. Therapeutic potential of chemokine receptor antagonists for liver disease. Expert Rev. Clin. Pharmacol. 4(4), 503-513 (2011
25. Lebre MC, Vergunst CE, Choi IY et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS ONE 6(7), e21772 (2011
26. Struthers M, Pasternak A. CCR2 antagonists. Curr. Top. Med. Chem. 10(13), 1278-1298 (2010).